Skip to main
DCGO

DocGo (DCGO) Stock Forecast & Price Target

DocGo (DCGO) Analyst Ratings

Based on 4 analyst ratings
Buy
Strong Buy 50%
Buy 25%
Hold 25%
Sell 0%
Strong Sell 0%

Bulls say

DocGo is projected to experience significant growth in their Mobile Health Services segment, with a potential contribution of $30 million from their recent acquisition of SteadyMD and further growth in virtual care services. However, a key concern is whether the company can decrease operating expenses enough to achieve their adjusted EBITDA target. Despite this challenge, the company has taken steps to reposition and improve their core medical transportation business, with a potential for $15-20 million in 2026 EBITDA. Overall, while uncertainties remain, there are positive indicators that DocGo is on the path to sustainable growth in the long term.

Bears say

DocGo is a healthcare provider that offers mobile health services, virtual care management, and transportation services. However, the company has struggled to scale its business and faces potential revenue headwinds in the future. Its current success is driven largely by COVID-related contracts, and there are risks involved due to government regulation and competition. While the company's business model and partnerships present opportunities for growth, it remains to be seen if they can effectively capitalize on them.

DocGo (DCGO) has been analyzed by 4 analysts, with a consensus rating of Buy. 50% of analysts recommend a Strong Buy, 25% recommend Buy, 25% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of DocGo and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About DocGo (DCGO) Forecast

Analysts have given DocGo (DCGO) a Buy based on their latest research and market trends.

According to 4 analysts, DocGo (DCGO) has a Buy consensus rating as of Aug 9, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $2.38, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $2.38, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

DocGo (DCGO)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.